Teva agrees to acquire Théramex and related companies from Merck Serono.
On October 28, Willkie client Teva Pharmaceutical Industries Ltd. and Merck Serono, a division of Merck KGaA announced that they have entered into a definitive agreement under which Teva will acquire Théramex and related companies from Merck Serono for €265 million. With over €100 million in revenue in 2009, Théramex offers a wide variety of women's health products in the areas of gynecology, osteoporosis, peri-menopause, menopause and contraceptives sold in 50 countries worldwide. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries.
Willkie also previously assisted Teva on its $8.9 billion acquisition of Barr Pharmaceuticals, its approximately $360 million acquisition of Bentley Pharmaceuticals, Inc., and its $400 million acquisition of CoGenesys, Inc.
The Willkie team advising Teva on the current transaction is led by Paris partner Eduardo Fernandez and includes associates Xavier Doumen and Alexandre Riou (corporate/M&A); partner David Tayar and associates Dounia Ababou, Agathe Richard and Lionela Nizet (competition law); and partner Vincent Brenot and associates Raphaëlle Buot de l'Epine and Iris Géniès (regulatory and environmental law). Gianluca Cattani led the team from Willkie's Milan and Rome offices, which included Antonio Panto and Daniele De Liberato (Italian law issues).